THE CHALLENGE QUESTION

How can we unite people living with psoriatic disease and their healthcare providers to achieve optimal health outcomes?

An Amgen initiative

*Amgen exercises diligence in ensuring compliance with local law and policy. All patient organizations are strongly encouraged to consult country specific law and compliance guidance before applying as certain countries are unable to receive these types of donations and grants based on local law or policy. Your submission could be impacted by these laws at any time throughout the application process. We appreciate your understanding and support.

THE CHALLENGE QUESTION

How can we unite people living with psoriatic disease and their healthcare providers to achieve optimal health outcomes?

APPLY NOW*

*Amgen exercises diligence in ensuring compliance with local law and policy. All patient organizations are strongly encouraged to consult country specific law and compliance guidance before applying as certain countries are unable to receive these types of donations and grants based on local law or policy. Your submission could be impacted by these laws at any time throughout the application process. We appreciate your understanding and support.

1	Does the solution effectively address the challenge question? How can we unite people living with psoriatic disease and their healthcare providers to achieve optimal health outcomes?
2	Is the intended audience clearly described?
3	Is the potential impact on the intended audience clearly described?
4	Have quantitative and qualitative metrics been defined?

UPLIFT surveyed approximately 4,700 people:¹

473 dermatologists
450 rheumatologists
3,806 people living with psoriatic disease

The survey took place in eight countries:

The survey builds upon findings from the 2012 Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey, a first-of-its-kind study conducted by Celgene that looked in-depth at the effect of psoriasis and psoriatic arthritis on people living with these conditions and evaluated the associated unmet treatment needs.

Perception of Disease Severity

People living with psoriasis who had limited skin involvement viewed their disease as more severe than how it would be categorized by common severity assessment measures, such as Body Surface Area (BSA).

Accessing Treatment

Despite more available treatment options, a significant proportion of people with psoriasis, regardless of disease severity, are still not receiving treatment.

Approximately 1/3 of patients in UPLIFT were not receiving any treatment

If more information is required, get in contact with us at UPLIFTInnovationChallenge@dna-comms.com.

APPLY NOW*

*Amgen exercises diligence in ensuring compliance with local law and policy. All patient organizations are strongly encouraged to consult country specific law and compliance guidance before applying as certain countries are unable to receive these types of donations and grants based on local law or policy. Your submission could be impacted by these laws at any time throughout the application process. We appreciate your understanding and support.

Reference:

Lebwohl M, et al. Evolution of Patient Perceptions of Psoriatic Disease: Results From the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey. Presented at: Winter Clinical Dermatology Conference. January 2021.